United Securities Tweaks Nahdi Medical's Price Target After Q2 Net Profit Miss

05:06 AM EDT, 08/06/2026 (MT Newswires) -- United Securities LLC downwardly revised its price target on Nahdi Medical (SASE:4164) after the pharmaceutical retailer's second-quarter results. "[We] believe subdued consumer demand, intense competitive dynamics, and ongoing geopolitical uncertainty will continue to weigh on near-term performance. Following the 2Q26 results, we maintain our 2026e revenue and earnings forecasts but marginally reduce our target price to SAR 104.53 per share to reflect a higher risk premium. Accordingly, we reiterate our Hold recommendation on the stock," analysts said Wednesday. The company logged a 9.7% annual decline in net profit to 215 million Saudi riyals, 4.1% below United Securities' estimate. Revenue, meanwhile, rose 5.8% year over year, which was broadly in line with the research firm's forecast.